RxNorm 1441528

tocilizumab 180 MG/ML [Actemra]

RxNorm Semantic Concepts

RxNorm semantic concepts for the RxCUI 1441528 unique identifier include: tocilizumab 180 MG/ML [Actemra] (5530846).

RxNorm Atom ID: 5530846 - Semantic Branded Drug Component
tocilizumab 180 MG/ML [Actemra]

RXCUI:
1441528 - RxNorm Unique Identifier for a concept (Concept ID)
LAT:
ENG - Language of the Term
RXAUI:
5530846 - Unique identifier for the atom (RxNorm Atom ID)
Is Prescribable?
YES - This drug is part of the RxNorm Current Prescribable Content, a subset of RxNorm that includes all drugs available for prescription in the United States. The Current Prescribable subset also includes over-the-counter drugs.
Concept Description:
tocilizumab 180 MG/ML [Actemra] - Description of concept identifier
Term Type (TTY):
SBDC - Term type in source with name and description
Term Type Name:
Semantic Branded Drug Component - Name of term type in source
Term Type Description:
Ingredient + Strength + Brand Name - Description of term type in source
Code:
1441528 - "Most useful" source asserted identifier. If the source vocabulary has more than one identifier, or a RxNorm-generated source entry identifier. (if the source vocabulary has none.)
Suppress Flag:
N
Suppressible flag. Values = N, O, Y, or E. N - not suppressible. O - Specific individual names (atoms) set as Obsolete because the name is no longer provided by the original source. Y - Suppressed by RxNorm editor. E - unquantified, non-prescribable drug with related quantified, prescribable drugs. NLM strongly recommends that users not alter editor-assigned suppressibility.
CVF:
4096 - Content view flag. RxNorm includes one value, '4096', to denote inclusion in the Current Prescribable Content subset. All rows with CVF='4096' can be found in the subset.
Source:
RXNORM - Concept source abbreviation
Source Name:
RxNorm Vocabulary - The official name for a source
Source Version:
20AA_240304F - The source version
Source Date:
March 04, 2024 - RxNorm data last updated
Source License Contact:
RxNorm Customer Service

U.S. National Library of Medicine
8600 Rockville Pike

Bethesda
MD
United States
20894
(888) FIND-NLM

[email protected]
https://www.nlm.nih.gov/research/umls/rxnorm/ - The source license contact information
Source Content Contact:
RxNorm Customer Service

U.S. National Library of Medicine
8600 Rockville Pike

Bethesda
MD
United States
20894
(888) FIND-NLM

[email protected]
https://www.nlm.nih.gov/research/umls/rxnorm/ - The source content contact information
Source Short Name:
RxNorm work done by the National Library of Medicine - The short name of a source as used by the NLM Knowledge Source Server

* This product uses publicly available data courtesy of the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Patient Education

Tocilizumab Injection


Tocilizumab injection is used alone or in combination with other medications to relieve the symptoms of certain types of arthritis and other conditions including: rheumatoid arthritis (a condition in which the body attacks its own joints, causing pain, swelling, and loss of function) in adults who have not been helped by other disease-modifying antirheumatic drugs (DMARDs), giant cell arteritis (a condition that causes swelling of blood vessels, especially in the scalp and head) in adults, systemic sclerosis-associated interstitial lung disease (SSc-ILD; also known as scleroderma-associated ILD: a lung disease that involves scarring of the lungs) in adults, polyarticular juvenile idiopathic arthritis (PJIA; a type of childhood arthritis that affects five or more joints during the first six months of the condition, causing pain, swelling, and loss of function) in children 2 years of age or older. systemic juvenile idiopathic arthritis (SJIA; a condition in children that causes inflammation in different areas of the body, causing fever, joint pain and swelling, loss of function, and delays in growth and development) in children 2 years of age or older, cytokine release syndrome (a severe and possibly life-threatening reaction) in adults and children 2 years of age or older after receiving certain immunotherapy infusions. Tocilizumab injection is in a class of medications called interleukin-6 (IL-6) receptor inhibitors. It works by blocking the activity of interleukin-6, a substance in the body that causes inflammation.
[Learn More]


* Please review the disclaimer below.